ArticleScientific reports2025

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities`.

Mashael Algethami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.